

RESEARCH ARTICLE


Three-dimensional (3D) brain microphysiological system for organophosphates and neurochemical agent toxicity screening

Lumei Liu¹✉, Youngmi Koo¹✉, Chukwuma Akwitti¹, Teal Russell¹, Elaine Gay², Daniel T. Laskowitz³, Yeoheung Yun¹* 

1 FIT BEST Laboratory, Department of Chemical, Biological, and Bio Engineering, North Carolina Agricultural and Technical State University, Greensboro, North Carolina, United States of America, **2** Center for Drug Discovery, RTI International, Research Triangle Park, Durham, North Carolina, United States of America, **3** Departments of Neurology, Anesthesiology, and Neurobiology, Brain Injury Translational Research Center, Duke University, Durham, North Carolina, United States of America

✉ These authors contributed equally to this work.

* yyun@ncat.edu



OPEN ACCESS

Citation: Liu L, Koo Y, Akwitti C, Russell T, Gay E, Laskowitz DT, et al. (2019) Three-dimensional (3D) brain microphysiological system for organophosphates and neurochemical agent toxicity screening. PLoS ONE 14(11): e0224657. <https://doi.org/10.1371/journal.pone.0224657>

Editor: Valentin Ceña, Universidad de Castilla-La Mancha, SPAIN

Received: May 17, 2019

Accepted: October 19, 2019

Published: November 8, 2019

Copyright: © 2019 Liu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by U.S. Department of Defense contact # D01 W911SR-14-2-0001-0010 awarded through the MSRDC Consortium (DTRA and ECBC) at North Carolina A & T State University, NIH NIGMS grant (ISC3GM113728, <https://www.nigms.nih.gov/Research/Pages/default.aspx>; YY is the recipient), NSF EAGER Grant (1649243, <https://www.nsf.gov/>

Abstract

We investigated a potential use of a 3D tetraculture brain microphysiological system (BMPS) for neurotoxic chemical agent screening. This platform consists of neuronal tissue with extracellular matrix (ECM)-embedded neuroblastoma cells, microglia, and astrocytes, and vascular tissue with dynamic flow and membrane-free culture of the endothelial layer. We tested the broader applicability of this model, focusing on organophosphates (OPs) Malathion (MT), Parathion (PT), and Chlorpyrifos (CPF), and chemicals that interact with GABA and/or opioid receptor systems, including Muscimol (MUS), Dextromethorphan (DXM), and Ethanol (EtOH). We validated the BMPS platform by measuring the neurotoxic effects on barrier integrity, acetylcholinesterase (AChE) inhibition, viability, and residual OP concentration. The results show that OPs penetrated the model blood brain barrier (BBB) and inhibited AChE activity. DXM, MUS, and EtOH also penetrated the BBB and induced moderate toxicity. The results correlate well with available *in vivo* data. In addition, simulation results from an *in silico* physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model that we generated show good agreement with *in vivo* and *in vitro* data. In conclusion, this paper demonstrates the potential utility of a membrane-free tetraculture BMPS that can recapitulate brain complexity as a cost-effective alternative to animal models.

Introduction

Chemical agents like organophosphates (OPs) pose a grave threat to soldiers, creating an urgent need to develop better *in vitro* models for studying neurotoxicity screening, as well as developing protective measures against chemical warfare agents and therapeutic interventions. Further, more than 60,000 tons of OP pesticides are produced and used every year in the United States,

[awardsearch/showAward?AWD_ID=1649243](#); YY is the recipient). These funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.

Competing interests: The authors have declared that no competing interests exist.

which poses a significant potential health risk [1]. OPs are usually ester ($\text{R-CO}_2\text{-R}$), amide (R-NH_2), or thiol (R-SH) derivatives of phosphonic acid ($\text{H}_3\text{O}_3\text{P}$). OPs inhibit acetylcholinesterase (AChE), leading to an accumulation of acetylcholine (ACh) that induces hypercholinergic activity as a result of continuous firing between pre- and post-synaptic neurons. This process causes lethal excitotoxicity, seizures, and brain damage [2, 3]. Another set of warfare agents are chemicals that interact with GABA and/or opioid receptors, which can cause acute neurotoxicity. There is a clear need to develop a realistic *in vitro* brain microphysiological system (BMPS) that recapitulates the activities, mechanical environment, and complex physiological responses of the brain and that can be used to rapidly screen large numbers of chemical warfare compounds.

Current 2D *in vitro* models do not reliably model nor predict brain physiology and do not recapitulate the continuous interaction of multiple tissues in the central nerve system (CNS). Transwell models, which use static cultures in multiple compartments separated by a rigid, porous membrane, have limited imaging capability and vascular function. Similarly, brain slices may provide a certain level of brain circuit function, but cannot replicate the complex, multifunctional, and integrated neuro-gliovascular-immune system needed for toxicity screening. Recently, organoid and spheroid models have been used to study brain development and dysfunction. There is a clear need to develop a dynamic 3D BMPS that can provide clinically relevant information for toxicity screening. Brain tissue models must (i) include different cell types, such as neurons, microglia, astrocytes, and endothelial cells with host extracellular matrix (ECM), and (ii) be able to replicate the spatiotemporal context of original brain tissue.

In a previous study, we successfully screened four OPs for neurotoxicity using a 3D tetraculture **microphysiological** platform [4]. In this paper, we use the same platform to screen the toxicity of an expanded set of OPs and chemical agents that interact with GABA and/or opioid receptors: agonists of GABA receptors Muscimol (MUS) and Ethanol (EtOH), and glutamate (NMDA) antagonist Dextromethorphan (DXM). We evaluated the neurotoxic agents for concentration-dependent effects on: 1) overall cell viability/toxicity, 2) penetration of the agents across the model blood brain barrier (BBB), and 3) inhibition of AChE activity in target neuron cells following exposure. We correlated the *in vitro* results with available *in vivo* data for the potential use of this platform in a high-content/throughput manner. Furthermore, we developed an *in silico* physiologically-based pharmacokinetic/pharmacodynamics (PBPK/PD) model to predict effective concentrations and correlated our results with the *in vitro* and *in vivo* data.

Material and methods

Chemical agent preparation

OPs Chlorpyrifos (CPF), Malathion (MT), and Parathion (PT) were purchased from Sigma-Aldrich (St. Louis, MO, USA) in neat form. They were dissolved in Dimethyl sulfoxide (DMSO) first, and then diluted to final concentration of 5% DMSO in Dulbecco's modified eagle's medium (DMEM, ATCC, Manassas, VA, USA) and then further diluted in DMEM to concentrations of 10^{-1} , 10^{-3} , 10^{-5} , and 10^{-7} M. Muscimol (MUS, Sigma-Aldrich, St. Louis, MO, USA) and Dextromethorphan (DXM, USP[™], Rockville, MD, USA) were diluted in DMEM to concentrations of 10^{-1} , 10^{-2} , 10^{-3} , and 10^{-4} mM. Pure Ethanol (EtOH) purchased from Sigma-Aldrich (St. Louis, MO, USA) was diluted in DMEM to concentrations of 500, 100, 20, and 5 mM. The DMSO-contained medium were used as control (CON): 5% DMSO in DMEM for OPs, DMEM for MUS, DXM and EtOH.

Cell culture

The complete culture medium for all cell lines was DMEM supplemented with 10% fetal bovine serum (ATLANTA Biologicals, Flowery Branch, GA, USA) and 1% Penicillin/

Streptomycin solution (HyClone Laboratories Inc., South Logan, UT, USA). Murine brain cell lines bEnd.3 (endothelial cells), N2a (neuroblastoma cells), and C8-D1A (astrocytes) were purchased from ATCC. Murine brain cell line BV-2 (microglia) was obtained from Dr. G. Jean Harry (National Institute of Environmental Health Sciences, Research Triangle Park, NC). All cell lines were maintained according to provided protocols and previous studies [5]. Briefly, the cells were cultured in 75 cm² flasks (Corning, NY, USA) separately, and medium was refreshed every other day until the cells reached $\geq 90\%$ confluency.

3D brain microphysiological system (BMPS)

The OrganoPlate (MIMETAS, Netherlands) was used to construct the 3D membrane-free microfluidic BMPS and the tissue construct method was described previously [4]. Briefly, collagen solution (Corning, Type I Rat Tail) was diluted in DMEM and the pH was neutralized to 7.0–7.4. Collagen preparation was performed on ice. N2a, C8-D1A, and BV-2 cells were re-suspended in the ECM at the following concentrations: N2a – 3.12×10^6 cells/mL, C8-D1A – 3.12×10^6 cells/mL, and BV-2 – 1.56×10^6 cells/mL. The cell-ECM mixture was added to the gel lane and incubated (37°C, 5% CO₂) for 1 h for gel polymerization. After polymerization, bEnd.3 cells were dispensed into the medium lane at a concentration of 1×10^7 cells/mL in DMEM. The plate was incubated against the side of the incubator at a 75° angle for 4 h to allow bEnd.3 cells to settle against the ECM. Then, 50 µL medium was added to the medium inlet and outlet. The plate was placed on an interval rocker (MIMETAS, The Netherlands) for medium perfusion inside the incubator (37°C, 5% CO₂). The rocker (switching between +7° and –7° inclination every 8 min) created a bi-directional flow with a mean flow rate of 2.02 µL/min and a mean shear rate of 0.13 Pa. Medium (50 µL each in the inlet and outlet) was refreshed every other day.

Compound exposure and residual measurement

After five days of 3D co-culture, different concentrations of prepared OPs (CPF, MT, and PT), MUS, DXM, and EtOH were added to the medium inlet of the neurovascular endothelial lane (blood lane). After 24 hours, the solution was removed from the blood lane and stored at –20°C. The residual concentrations of the OPs were measured by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using a triple quadrupole mass spectrometer coupled with a Shimadzu Prominence High Performance LC (HPLC) system (API 3200, AB Sciex).

Cell viability

The LIVE/DEAD[®] Viability/Cytotoxicity Kit for mammalian cells (Invitrogen, Carlsbad, CA) was used to test viability. After washing cells twice with PBS, cells were incubated for 30 min in 2 µM Calcein AM, 4 µM Ethidium homodimer-1 (EthD-1), and 2 µg/mL Hoechst to stain live cells green, dead cells red, and nuclei blue, respectively. Viability was calculated using ImageJ software (US National Institutes of Health, Bethesda, MD) by dividing live cell number by total cell number and multiplying by 100%.

Acetylcholinesterase (AChE) activity assay

The Molecular Probes[™] Amplex[™] Acetylcholine (ACh)/Acetylcholinesterase Assay Kit was used to measure AChE activity. Briefly, standards and working solutions were prepared according to the manufacturer's instruction. Samples and standards were incubated in working solution for 30 min. The fluorescence was read using a CLARIOstar microplate reader (BMG LABTECH, Cary, NC, USA) at 25°C.

Data analysis

Cell viability, AChE activity, and residual concentration data (Mean $\pm$ Standard deviation) were plotted using Microsoft Excel. The correlation of *in vitro* AChE activity (inhibitor concentration 50%, IC₅₀) and viability (lethal concentration 50%, LC₅₀) data with *in vivo* lethal dose 50% (LD₅₀) data was analyzed using Origin[®] 2018 (OriginLab, Northampton, MA, USA).

Physiologically-based pharmacokinetic /pharmacodynamic (PBPK/PD) model

A PBPK/PD model for AChE inhibition was developed for CPF and diisopropylfluorophosphate (DFP) using MATLAB Simbiology Toolbox. The model has multiple compartments of lung, brain, kidney, liver, diaphragm, slowly perfused and rapid perfused tissues, arterial blood and venous blood. In terms of murine-based PBPK/PD modeling of DFP toxicity, this paper followed the previous work from Gearhart et. al. [6], which includes DFP tissue/blood partition coefficients, rates of DFP hydrolysis by esterases, and DFP-esterase bimolecular inhibition rate constants. The model includes two DFP-based esterase reactions: 1) A esterase (AEST) hydrolysis to the non-inhibitory product diisopropylphosphoric acid (DIP) and 2) B esterase (BEST) hydrolysis, which inhibits AChE enzymatic activity. The same determinants were used for the case of CPF and follow previous work [7]. This murine-based CPF toxicity PBPK/PD model with esterase dynamics integrates target tissue dosimetry and dynamic response (i.e. esterase inhibition) describing the uptake, metabolism, and disposition of CPF, CPF-oxon, and 3,5,6-trichloro-2-pyridinol (TCP), and the associated cholinesterase (ChE) inhibition kinetics in blood and tissue following CPF exposure. AEST is allocated to blood, liver, kidney, rapid perfusion, and brain compartments. For both OPs, the hydrolysis reaction is modeled by the Michaelis-Menten kinetics with V_{max} and K_m parameters measured *in-vitro*.

Results

Microfluidic 3D BMPS platform

Microfluidic brain tissue chips were constructed using the 2-lane OrganoPlate (MIMETAS, Netherlands), with the construct method previously described [7]. Brain tissue chips consisted




Fig 1. Brain microphysiological system (BMPS). (A) BMPS platform design. (a) A Mimetas OrganoPlate consisting of 384 wells; (b) The schematic structure of two-lane microfluidic chamber consisting of 4 wells; (c) The schematic design (top view) of the observation column; (d) The incubation of OrganoPlate in a dynamic perfusion condition; (e) Expecting cells co-culture after incubation with 220 μ m height, 325 μ m perfusion lane and 375 μ m brain lane. (B) Immunofluorescent images of cells co-culture. (f) Live (green)/dead (red) images before OP exposure (nucleus are stained by Hoechst to blue) and (h) after OP exposure (nucleus are stained by Hoechst to blue).

<https://doi.org/10.1371/journal.pone.0224657.g001>

of a vascular lane and brain lane with cell-gel matrix, which were separated by a capillary pressure barrier called a phase guide (Pg). The Pg separates the gel and fluid phases for membrane-free endothelial cell adhesion and BBB formation against the cell-gel matrix [8, 9]. The brain tissue constructs were placed on a rocker inside an incubator, creating dynamic medium perfusion in the vascular lane, which consisted of endothelial cells, while the brain lane consisted of neurons, astrocytes, and microglia in ECM.

OP toxicity with different exposure times

Using the BMPS platform, we tested the toxicity of CPF at concentrations of 10^{-1} , 10^{-3} , 10^{-5} , and 10^{-7} M for 6-, 12-, and 24-hour exposure times. Cell viability, AChE activity, and residual CPF concentration were measured. As shown in Fig 2, cell viability and AChE activity decreased with an increase in CPF concentration and exposure time (Figs 2A and 1B). Residual CPF also increased with an increase in CPF concentration (Fig 2C). The results show that after 6 and 12 hours of exposure, viability decreased from 100% to 60% with an increase in




Fig 2. Time-dependent viability(A), AChE activity (B), and residual CPF concentration (C) measured in 3D BMPS platform after varying concentrations of CPF exposure.

<https://doi.org/10.1371/journal.pone.0224657.g002>

CPF concentration, and at 24 hours, viability dramatically decreased from 100% to 10% (Fig 1A). AChE activity was also greatly impacted after 24 hours (Fig 2B). Fig 3 shows viability (lethal concentration 50%, LC₅₀) decreased with an increase in exposure time.

OP toxicity with 24-hour exposure times

We further tested CPF, MT, and PT at four different concentrations (10^{-1} , 10^{-3} , 10^{-5} , and 10^{-7} M) using the BMPS platform. We measured cell viability, AChE activity, and residual concentration after 24 hours of exposure. The results show that CPF, MT, and PT all penetrated through the BBB and inhibited AChE activity, inducing cell toxicity in the brain tissue construct. The cell viability (Fig 4A) and AChE activity (Fig 4B) of the brain lane decreased with an increase in OP concentration for all three OPs. There was a greater decrease in the AChE activity of cells treated with MT and PT compared to cells treated with CPF. The results show that both MT and PT had higher residual concentrations than CPF (Fig 4C).

In vitro-in vivo data correlation

Our previous study showed an *in vitro-in vivo* correlation with available toxicity data for four OPs [4]. In this study, we expanded the set of OPs for a more accurate and complete correlation that includes the previous data. Table 1 shows a summary of available *in vivo* LD₅₀ data and our estimated LC₅₀ (viability) and IC₅₀ (AChE activity) data [10–14]. As shown in Fig 5, our estimated LC₅₀ and IC₅₀ show good correlation with *in vivo* data. Based on our *in vitro*




Fig 3. Viability (LC₅₀) after CPF exposure at varying time points (hours) using 3D BMPS platform. The error bars were shown as 95% confidence intervals (CI) (profile likelihood).

<https://doi.org/10.1371/journal.pone.0224657.g003>




Fig 4. OP (MT, PT, and CPF) exposure results with 3D BMPS model. (A) Viability, (B) AChE activity, and (C) OP residual concentration data. Controls (without OP treatment) are labeled as CON.

<https://doi.org/10.1371/journal.pone.0224657.g004>

BMPS model and *in vivo* data from the literature [15], PT induces greater neurotoxicity than MT and CPF.

Table 1. Comparison of *in vitro* 3D BMPS model data with *in vivo* data for OP toxicity.

Chemical	AChE activity (IC ₅₀ , M) (95% CI)	Toxicity (LC ₅₀ , M) (95% CI)	<i>In vivo</i> (LD ₅₀ , mg/kg) (toxicity source)
Chlorpyrifos (CPF)	2.735E-1 (7.634E-4 ~ noncomplete CI)	3.949E-4 (1.118E-4 ~ 8.145E-4)	96 (Oral-human)
Malathion (MT)	1.805E-3 (7.670E-4 ~ 5.600E-3)	1.171E-3 (9.216E-4 ~ 1.494E-3)	369 (Oral-rat)
Parathion (PT)	4.338E-6 (1.113E-6 ~ 1.036E-5)	8.924E-3 (5.727E-3 ~ 1.409E-2)	25 (Oral-human)
Diisopropyl fluorophosphate (DFP)	1.863E-3 (9.180E-4 ~ 4.635E-3)	1.781E-5 (5.007E-8 ~ 2.251)	6 (Oral-rat)
Dimethyl methylphosphonate (DMMP)	4.159E-1 (1.253E-1 ~ noncomplete CI)	1.217E-1 (1.651E-2 ~ 1.763)	8210 (Oral-rat)
Diethyl methylphosphonate (DEMP)	1.971E-1 (9.826E-2 ~ 4.933E-1)	2.307E-1 (2.415E-1 ~ noncomplete CI)	800 (Intraperitoneal-mouse)
Diethyl cyanophosphonate (DECP)	1.075E-05 (2.475E-6 ~ 5.813E-5)	8.948E-6 (5.919E-9 ~ 3.906E-3)	1.4 (Intraperitoneal-mouse)
Diethyl chlorophosphate (DCP)	8.688E-06 (1.603E-6 ~ 4.302E-5)	4.094E-3 (6.202E-4 ~ 7.146E-2)	11 (Oral-rat)

<https://doi.org/10.1371/journal.pone.0224657.t001>




Fig 5. *In vitro* AChE activity and viability correlation with *in vivo* LD₅₀ data. A. Estimated IC₅₀ for *in vitro* AChE activity vs. *in vivo* LD₅₀ for DMMP, DEMP, DECP, DCP, CPF, MT and PT ($R = 0.7063$, $P = 0.0502$); B. Log-estimated LC₅₀ for *in vitro* viability vs. *in vivo* LD₅₀ for DMMP, DEMP, DECP, DCP, CPF, MT and PT ($R = 0.7285$, $P = 0.0404$).

<https://doi.org/10.1371/journal.pone.0224657.g005>

Toxicity of chemical agents that interact with GABA and/or opioid receptors

We screened the toxicity of selected chemical agents MUS and DXM at concentrations of 10^{-1} , 10^{-2} , 10^{-3} , and 10^{-4} mM and EtOH at concentrations of 500, 100, 20, 5 mM, which were added to the blood lane of the brain tissue chips. After 24 hours of exposure, we found that viability decreased with an increase in concentration for all agents (S1 Fig). MUS decreased viability to a greater extent than DXM at the same concentration. Results also showed that EtOH is much less toxic to the brain compared to MUS and DXM, as it induced similar toxicity to MUS and DXM even though it was added at much higher concentrations. Correlation of our viability data (LC₅₀ and LD₅₀) with available *in vivo* data for MUS [16], DXM [17], and EtOH [18] was summarized in Table 2. As shown in Fig 6, there is a linear correlation between *in vivo* data and our *in vitro* data from the BMPS model ($R = 0.9843$).

In silico PBPK/PD model

A PBPK/PD model was developed for DFP and CPF toxicity based on the Gearhart and Timchalk paper [6, 7]. The PBPK/PD model for DFP and CPF was validated in terms of AChE inhibition and OP concentration change. S2 Fig shows AChE concentration in the blood and brain after IV injection of DFP. AChE increased immediately and decreased in a very short time, ~ 2 minutes, which correlates with existing experimental data in the literature. Next, CPF exposure via IV injection was simulated using a whole-body PBPK/PD model. S3 Fig shows AChE activity after CPF exposure at concentrations of 40 mg/kg, 20 mg/kg, and 1 mg/kg, with results also correlating with previous literature [7]. The results were further correlated with available *in vivo* data [7, 19, 20] and our *in vitro* data from the BMPS platform. Fig 7 shows the correlation between *in vivo* LD₅₀ data and our PBPK/PD IC₅₀ data, which shows good agreement. All results confirmed that DFP is more toxic than CPF.

Table 2. Comparison of *in vitro* 3D BMPS model data with *in vivo* LD₅₀ data on MUS, DXM, and EtOH toxicity.

Chemical	Toxicity		<i>In vivo</i>	
	(LC ₅₀ , mM) (95% CI)		(LD ₅₀ , mg/kg) (toxicity source)	
MUS	1.159E-3	(3.592E-5 ~ 3.677E-2)	2.5	(Oral-mouse) [16]
DXM	3.863E-2	(1.860E-3 ~ 8.089E-1)	116	(Oral-rat) [17]
EtOH	5.240E1	(1.797E1 ~ 1.654E2)	7060	(Oral-rat) [18]

<https://doi.org/10.1371/journal.pone.0224657.t002>




Fig 6. Correlation between *in vitro* viability and *in vivo* LD₅₀ data. Log-estimated LC₅₀ for *in vitro* viability vs. *in vivo* LD₅₀ for MUS, EtOH, and DXM ($R = 0.9843$).

<https://doi.org/10.1371/journal.pone.0224657.g006>

Discussion

Chemical warfare agents and pesticides, including agonists and antagonists of neurotransmitters, can disrupt the CNS and mediate neurotoxicity. In this study, we constructed a BMPS (Fig 1) consisting of 1) ECM-embedded brain cells (neurons, astrocytes, and microglia) and 2) a membrane-free endothelial cell vascular structure with dynamic medium perfusion. This BMPS platform simulated cell-to-cell crosstalk in ECM and BBB physiology in a high-throughput manner [21]. In our previous study, we used this platform to evaluate four OPs for concentration-dependent neurotoxic effects [4]. In this paper, we further validated the BMPS model with an expanded set of OPs and chemical agents that interact with GABA and/or opioid receptors. All the chemicals, including OPs (MT, PT, and CPF) and MUS, DXM, EtOH, penetrated through the simulated BBB and induced neurotoxicity in the ECM-embedded brain cells. For OPs, we tested CPF first to determine its time-dependent toxicity (Figs 2 and 3). As expected, cell viability and AChE activity decreased with an increase in CPF exposure time. Similarly, we performed 24-hour exposures with CPF, MT, and PT and measured OP-induced toxicity. OP toxicity was concentration-dependent and comparable between OPs. The results indicate that CPF is less toxic than MT and PT (Fig 4A and 4B). The residual OP concentration data showed that CPF penetrated the BBB to a greater extent than MT and PT (Fig 4C). In the *in vivo-in vitro* correlation analysis, a large population of tested samples further validated the reliability of this platform [22]. *In vitro* results from the BMPS positively correlate with *in vivo* toxicity. The mechanisms of OP toxicity are not limited to AChE activity inhibition, as they also include other mechanisms, such as glutamate-mediated excitotoxicity, diazepam-induced




Fig 7. Correlation between *in silico* PBPK/PD model IC_{50} , *in vitro* BMPS IC_{50} , and *in vivo* LD_{50} data.

<https://doi.org/10.1371/journal.pone.0224657.g007>

apoptotic neuronal death [23], and mitochondrial-mediated and caspase-regulated apoptosis [24–27]. This also explains the extreme descent in viability but mild decrease even some increase in AChE activity when exposed to Ops (e.g. Fig 3, CPF viability and AChE activity). The BMPS platform we explored here can possibly be a useful model to study complex physiology and toxicity mechanisms. Furthermore, this platform can provide knowledge about the differences between *in vitro* and *in vivo* models for neurotoxicology [28].

We tested the toxicity of MUS, DXM, and EtOH at different concentrations, which were determined according to previous studies [29–31]. Cell viability decreased to a greater extent following MUS exposure compared to DXM at the same concentration, indicating that MUS is more toxic than DXM (Fig 6, $R = 0.9843$). Much higher concentrations of EtOH were needed to attain similar viability results, indicating that EtOH has a much lower toxicity than MUS and DXM. EtOH and MUS are agonists of GABA receptors and the effects of EtOH are not as severe as MUS. The correlation between our viability data and *in vivo* LD_{50} data is with a high coefficient in the linear correlation ($R = 0.9843$). DXM has inhibitory effects on glutamate-induced neurotoxicity as a NMDA receptor antagonist [32]. Previously, researchers have studied the neuroprotective effect of DXM [32, 33], and our toxicity screening study provides a potential dose-dependent model for the toxic or protective effects of DXM. The common mechanism of MUS, EtOH, and DXM is that they inhibit signal transmission and decrease neuron activity, thus disrupting the CNS [34–36]. In regards to this mechanism, MUS is more potent than DXM and EtOH at similar and lower concentrations.

The correlation between available *in vivo* LD_{50} data and our simulated AChE IC_{50} data for DFP and CPF was used to validate our *in silico* PBPK/PD model. The correlation shows good agreement between *in vivo* data and our *in vitro* BMPS data (Fig 7). A comparison of both compounds shows that DFP is more toxic than CPF, which is consistent with previous

literature [4]. As more data for the parameters of the PBPK/PD model become available, other chemical agents can be validated in the future.

We confirmed that the BMPS is a feasible, repeatable, and reproducible platform for toxicity screening of chemical agents. The cell viability and AChE activity results from this platform show positive correlation with available *in vivo* toxicity data. Thus, this platform can be used to reliably predict the *in vivo* effect, toxic or beneficial, of other candidate compounds.

Supporting information

S1 Fig. Viability (%) of brain lane with treatment of MUS (A), EtOH (B) and DXM (C) for 24 hours.

(TIF)

S1 Table. Model parameters for AChE inhibition for DFP and CPF. The parameters are cited from literature [19].

(DOCX)

S2 Table. Other parameters for PBPK/PD of DFP and CPF modelling in rat brain. The parameters are cited from literature [19].

(DOCX)

S2 Fig. Time-course of plasma and brain AChE activity (mg/mL) after IV injection of 1 mg/kg DFP simulated by *in silico* PBPK/PD model. A. Short term within 30 minutes; B. Intermediate term within 1 day; C. Long term over 200 hours.

(TIF)

S3 Fig. AChE activity in brain from whole-body PBPK/PD model under CPF, exposure of 40 mg/kg (A), 20 mg/kg (B), and 1 mg/kg (C) within 1 day.

(TIF)

Acknowledgments

The authors thank Drs. Sonia Grego, Brain Hawkins at RTI International (Research Triangle Park, NC, USA), and Dr. Remko van Vught at MIMETAS (Leiden, Netherlands).

Author Contributions

Conceptualization: Youngmi Koo, Daniel T. Laskowitz, Yeoheung Yun.

Data curation: Lumei Liu, Chukwuma Akwitti.

Funding acquisition: Yeoheung Yun.

Investigation: Yeoheung Yun.

Methodology: Lumei Liu, Youngmi Koo, Chukwuma Akwitti, Teal Russell, Yeoheung Yun.

Project administration: Yeoheung Yun.

Resources: Elaine Gay.

Software: Lumei Liu.

Supervision: Yeoheung Yun.

Validation: Lumei Liu.

Visualization: Lumei Liu, Teal Russell.

Writing – original draft: Lumei Liu.

Writing – review & editing: Lumei Liu, Youngmi Koo, Teal Russell, Elaine Gay, Yeoheung Yun.

References

1. Eto M. Organophosphorus pesticides: CRC press; 2018.
2. Slotkin T. Does early-life exposure to organophosphate insecticides lead to prediabetes and obesity? *Reprod Toxicol*. 2011; 31(3):297–301. <https://doi.org/10.1016/j.reprotox.2010.07.012> PMID: 20850519
3. Slotkin TA, Levin ED, Seidler FJ. Comparative Developmental Neurotoxicity of Organophosphate Insecticides: Effects on Brain Development Are Separable from Systemic Toxicity. *Environmental Health Perspectives*. 2006; 114(5):746–51. <https://doi.org/10.1289/ehp.8828> PubMed PMID: PMC1459930. PMID: 16675431
4. Koo Y, Hawkins BT, Yun Y. Three-dimensional (3D) tetra-culture brain on chip platform for organophosphate toxicity screening. *Scientific reports*. 2018; 8(1):2841. <https://doi.org/10.1038/s41598-018-20876-2> PMID: 29434277
5. Hawkins BT, Hu T, Dougherty ER, Grego S. Modeling neuroinflammatory effects after chemical exposures in a scalable, three-dimensional cell culture system. *Applied in vitro toxicology*. 2016; 2(4):223–34.
6. Gearhart JM, Jepson GW, Clewell HJ, Andersen ME, Conolly RB. Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. *Environmental health perspectives*. 1994; 102(suppl 11):51–60.
7. Timchalk C, Nolan R, Mendrala A, Dittenber D, Brzak K, Mattsson J. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. *Toxicological Sciences*. 2002; 66(1):34–53. <https://doi.org/10.1093/toxsci/66.1.34> PMID: 11861971
8. Yi Y, Park J, Lim J, Lee CJ, Lee S-H. Central nervous system and its disease models on a chip. *Trends in biotechnology*. 2015; 33(12):762–76. <https://doi.org/10.1016/j.tibtech.2015.09.007> PMID: 26497426
9. Rahman NA, Rasil ANaHM, Meyding-Lamade U, Craemer EM, Diah S, Tuah AA, et al. Immortalized endothelial cell lines for in vitro blood–brain barrier models: A systematic review. *Brain research*. 2016; 1642:532–45. <https://doi.org/10.1016/j.brainres.2016.04.024> PMID: 27086967
10. Lenz DE, Clarkson ED, Schulz SM, Cerasoli DM. Butyrylcholinesterase as a therapeutic drug for protection against percutaneous VX. *Chemico-biological interactions*. 2010; 187(1–3):249–52. <https://doi.org/10.1016/j.cbi.2010.05.014> PMID: 20513442
11. EVARREST® Fibrin Sealant Patch, authors FDA Approval Letter. 2012.
12. Jo SH, Mathiasen RA, Gurushanthaiah D. Prospective, randomized, controlled trial of a hemostatic sealant in children undergoing adenotonsillectomy. *Otolaryngology—Head and Neck Surgery*. 2007; 137(3):454–8. <https://doi.org/10.1016/j.otohns.2006.09.020> PMID: 17765775
13. Mozet C, Prettin C, Dietze M, Fickweiler U, Dietz A. Use of Floseal and effects on wound healing and pain in adults undergoing tonsillectomy: randomised comparison versus electrocautery. *European Archives of Oto-Rhino-Laryngology*. 2012; 269(10):2247–54. <https://doi.org/10.1007/s00405-011-1904-4> PMID: 22207530
14. Nesheim O, Criswell J. Pesticide Applicator Certification Series: toxicity of pesticides [LD50 values, includes lists of common and trade names]. OSU extension facts-Cooperative Extension Service, Oklahoma State University (USA). 1982.
15. Koziol FS, Witkowski JF. Synergism studies with binary mixtures of permethrin plus methyl parathion, chlorpyrifos, and malathion on European corn borer larvae. *Journal of Economic Entomology*. 1982; 75(1):28–30.
16. Budavari S. The Merck Index, an encyclopedia of chemical drug, and biologicals. Merck, 1989.
17. Echave M, Oyagüez I, Casado MA. Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review. *BMC surgery*. 2014; 14(1):111.
18. Itzhak BRaB. The Risks of Haemostatic Materials in Tonsillectomy. *Archives of Otolaryngology and Rhinology*. 2015; 1(2):046–7.
19. Gearhart JM, Jepson GW, Clewell III HJ, Andersen ME, Conolly RB. Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. *Toxicology and applied pharmacology*. 1990; 106(2):295–310. [https://doi.org/10.1016/0041-008x\(90\)90249-t](https://doi.org/10.1016/0041-008x(90)90249-t) PMID: 2256118

20. Poet TS, Timchalk C, Hotchkiss JA, Bartels MJ. Chlorpyrifos PBPK/PD model for multiple routes of exposure. *Xenobiotica*. 2014; 44(10):868–81. <https://doi.org/10.3109/00498254.2014.918295> PMID: 24839995
21. Wevers NR, Van Vught R, Wilschut KJ, Nicolas A, Chiang C, Lanz HL, et al. High-throughput compound evaluation on 3D networks of neurons and glia in a microfluidic platform. *Scientific reports*. 2016; 6:38856. <https://doi.org/10.1038/srep38856> PMID: 27934939
22. Hole G. Eight things you need to know about interpreting correlations. 2014.
23. Rush T, Liu X, Hjelmhaug J, Lobner D. Mechanisms of chlorpyrifos and diazinon induced neurotoxicity in cortical culture. *Neuroscience*. 2010; 166(3):899–906. <https://doi.org/10.1016/j.neuroscience.2010.01.025> PMID: 20096330
24. Park JH, Ko J, Hwang J, Koh HC. Dynamin-related protein 1 mediates mitochondria-dependent apoptosis in chlorpyrifos-treated SH-SY5Y cells. *Neurotoxicology*. 2015; 51:145–57. <https://doi.org/10.1016/j.neuro.2015.10.008> PMID: 26598294
25. Carlson K, Jortner BS, Ehrich M. Organophosphorus compound-induced apoptosis in SH-SY5Y human neuroblastoma cells. *Toxicology and applied pharmacology*. 2000; 168(2):102–13. <https://doi.org/10.1006/taap.2000.8997> PMID: 11032765
26. Kashyap M, Singh A, Siddiqui M, Kumar V, Tripathi V, Khanna V, et al. Caspase cascade regulated mitochondria mediated apoptosis in monocrotophos exposed PC12 cells. *Chemical research in toxicology*. 2010; 23(11):1663–72. <https://doi.org/10.1021/tx100234m> PMID: 20957986
27. Kashyap MP, Singh AK, Kumar V, Yadav DK, Khan F, Jahan S, et al. Pkb/Akt1 mediates Wnt/GSK3 β / β -catenin signaling-induced apoptosis in human cord blood stem cells exposed to organophosphate pesticide monocrotophos. *Stem cells and development*. 2012; 22(2):224–38. <https://doi.org/10.1089/scd.2012.0220> PMID: 22897592
28. Tiffany-Castiglioni E, Ehrich M, Dees L, Costa L, Kodavanti P, Lasley S, et al. Bridging the gap between in vitro and in vivo models for neurotoxicology. *Toxicological sciences: an official journal of the Society of Toxicology*. 1999; 51(2):178–83.
29. Ariwodola OJ, Weiner JL. Ethanol potentiation of GABAergic synaptic transmission may be self-limiting: role of presynaptic GABAB receptors. *Journal of Neuroscience*. 2004; 24(47):10679–86. <https://doi.org/10.1523/JNEUROSCI.1768-04.2004> PMID: 15564584
30. Chen C-L, Cheng M-H, Kuo C-F, Cheng Y-L, Li M-H, Chang C-P, et al. Dextromethorphan Attenuates NADPH Oxidase-regulated GSK-3 β and NF- κ B Activation and Reduces Nitric Oxide Production in Group A Streptococcal Infection. *Antimicrobial agents and chemotherapy*. 2018; AAC. 02045–17.
31. Van den Pol AN, Obrietan K, Chen G. Excitatory actions of GABA after neuronal trauma. *Journal of Neuroscience*. 1996; 16(13):4283–92. <https://doi.org/10.1523/JNEUROSCI.16-13-04283.1996> PMID: 8753889
32. Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. *The neurologist*. 2007; 13(5):272–93. <https://doi.org/10.1097/NRL.0b013e3180f60bd8> PMID: 17848867
33. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. *Journal of Pharmacology and Experimental Therapeutics*. 2003; 305(1):212–8. <https://doi.org/10.1124/jpet.102.043166> PMID: 12649371
34. Larson TA, Wang T-W, Gale SD, Miller KE, Thatra NM, Caras ML, et al. Postsynaptic neural activity regulates neuronal addition in the adult avian song control system. *Proceedings of the National Academy of Sciences*. 2013; 201310237.
35. Tateno M, Saito T. Biological studies on alcohol-induced neuronal damage. *Psychiatry investigation*. 2008; 5(1):21–7. <https://doi.org/10.4306/pi.2008.5.1.21> PMID: 20046404
36. Ziemann U, Chen R, Cohen LG, Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. *Neurology*. 1998; 51(5):1320–4. <https://doi.org/10.1212/wnl.51.5.1320> PMID: 9818853